Is Baxter International (BAX) Stock Still Below Fair Value After A 66% Fall?
Baxter International has delivered a steep share price decline over five years, yet the stock now screens as cheap on both an intrinsic value estimate and traditional valuation multiples. That mix of long term pain and current discount is what investors are trying to make sense of today.
- The share price has fallen 66.5% over five years, which signals investors have heavily marked down expectations for the business.
- Future cash generation from Baxter International's medical products portfolio can support the current valuation, while any pressure on margins or balance sheet flexibility may limit how quickly that value is realized.
- The company scores 5 out of 5 on the broader valuation checks, which points to Baxter International looking inexpensive across most standard measures.
The issue now is whether the current discount to the Discounted Cash Flow (DCF) intrinsic value estimate reflects lingering caution or an opportunity that the market has priced too harshly.
Scan other deep value setups in healthcare by lining up Baxter International against 49 high quality undervalued stocks that also combine discounted pricing with solid fundamentals.
Is Baxter International a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model here uses Baxter International's projected free cash generation to estimate what the shares could be worth today. Over the latest twelve months, the group produced about $850.3 million of free cash flow in reporting currency terms, and the model assumes that these cash flows grow rather than shrink over time. Plugging those projections into a 2 Stage Free Cash Flow to Equity framework gives an intrinsic value of about $36.09 per share.
Compared with the current market price, that DCF outcome implies the stock trades at a 31.1% discount. On these assumptions, the cash flow profile of Baxter International supports a higher equity value than the market is currently assigning.
On this DCF view, Baxter International appears undervalued relative to the cash flows investors are projecting today.
Our Discounted Cash Flow (DCF) analysis suggests Baxter International is undervalued by 31.1%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.
Does Baxter International Look Undervalued on Sales?
Price to sales fits Baxter International because investors often focus on revenue-based metrics for medical equipment suppliers where earnings can be noisy. On this yardstick, Baxter trades on a P/S of about 1.1x, compared with roughly 3.0x for the wider Medical Equipment sector and a peer group average near 7.9x.
The fair P/S ratio for Baxter International is estimated at about 1.4x, which still sits above the current multiple. That gap indicates the market is pricing the stock below what the model implies given its sector, risk profile, and financial characteristics. In other words, revenue is being valued more conservatively here than both the industry average and this tailored benchmark.
On the P/S multiple, Baxter International appears undervalued relative to both sector norms and the fair ratio estimate.
See what the numbers say about this price — find out in our valuation breakdown.
The Baxter International Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Baxter International valuation puzzle leaves off. They explain, in plain terms, what kind of future for growth, profit margins and earnings would need to hold for the stock to be priced meaningfully higher or lower than it is today. Each one then presents that fair value view as a thesis about Baxter International's business that you can revisit over time to see how it holds up against new information.
Community views on Baxter International are split between a repair story that is still mispriced and a business facing longer term erosion in its hospital-focused lines.
Bull case: 13% undervalued
"Baxter's strengthened focus on innovation, including new product launches in advanced infusion systems, AI-enabled devices, and compounding, aligns with growing demand for efficient, digitalized, and connected healthcare equipment…"
Read the full Bull Case to see why Baxter International could be undervalued
Bear case: 8% overvalued
"Accelerating adoption of preventive care and at-home digital health solutions is reducing demand for traditional hospital-based therapies, which underpin a major share of Baxter's product portfolio…"
Read the full Bear Case to see why Baxter International could be overvalued
Do you think there's more to the story for Baxter International? Head over to our Community to see what others are saying!
The Bottom Line
Baxter International screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and on revenue based multiples, which sends a consistent message that the current price bakes in a lot of caution. That gap only really closes if either cash generation underwhelms or the market keeps assigning a low P/S because confidence in the business model does not rebuild. For investors, the real swing factor is whether margins and balance sheet flexibility stabilise enough for that perceived discount to narrow rather than turn into a long running value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com